BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37638533)

  • 1. Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Totsune T; Baba T; Sugimura Y; Oizumi H; Tanaka H; Takahashi T; Yoshioka M; Nagamatsu KI; Takeda A
    Mov Disord; 2023 Nov; 38(11):2053-2063. PubMed ID: 37638533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-phase
    Kim MS; Park DG; An YS; Yoon JH
    Eur J Neurol; 2023 Feb; 30(2):344-352. PubMed ID: 36288409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease.
    Umehara T; Oka H; Nakahara A; Shiraishi T; Sato T; Matsuno H; Komatsu T; Omoto S; Murakami H; Iguchi Y
    J Parkinsons Dis; 2021; 11(2):665-673. PubMed ID: 33361609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between heart rate variability and striatal dopamine depletion in Parkinson's disease.
    Kitagawa T; Umehara T; Oka H; Shiraishi T; Sato T; Takatsu H; Nakahara A; Matsuno H; Bono K; Omoto S; Murakami H; Sengoku R; Iguchi Y
    J Neural Transm (Vienna); 2021 Dec; 128(12):1835-1840. PubMed ID: 34559319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.
    Benítez-Rivero S; Marín-Oyaga VA; García-Solís D; Huertas-Fernández I; García-Gómez FJ; Jesús S; Cáceres MT; Carrillo F; Ortiz AM; Carballo M; Mir P
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):122-9. PubMed ID: 22906618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing speed is related to striatal dopamine transporter availability in Parkinson's disease.
    Vriend C; van Balkom TD; van Druningen C; Klein M; van der Werf YD; Berendse HW; van den Heuvel OA
    Neuroimage Clin; 2020; 26():102257. PubMed ID: 32344372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FP-CIT and MIBG scintigraphy in early Parkinson's disease.
    Spiegel J; Möllers MO; Jost WH; Fuss G; Samnick S; Dillmann U; Becker G; Kirsch CM
    Mov Disord; 2005 May; 20(5):552-61. PubMed ID: 15645531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study.
    Tiraboschi P; Corso A; Guerra UP; Nobili F; Piccardo A; Calcagni ML; Volterrani D; Cecchin D; Tettamanti M; Antelmi L; Vidale S; Sacco L; Merello M; Stefanini S; Micheli A; Vai P; Capitanio S; Gabanelli SV; Riva R; Pinto P; Biffi AM; Muscio C;
    Ann Neurol; 2016 Sep; 80(3):368-78. PubMed ID: 27398636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Extrastriatal
    Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [No Abstract]   [Full Text] [Related]  

  • 17. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
    Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes.
    Boccalini C; Carli G; Pilotto A; Padovani A; Perani D
    Neurobiol Dis; 2022 Jun; 167():105668. PubMed ID: 35219854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
    Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
    Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Takei T; Terae S; Tajima Y
    Parkinsonism Relat Disord; 2018 May; 50():37-41. PubMed ID: 29449184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.